
Immunotherapy increases overall survival in TNBC, according to the Keynote-355 study presented at the ESMO Congress
For the first time, immunotherapy added to chemotherapy has improved overall survival in metastatic triple-negative breast cancer, as demonstrated by the Keynote-355 study, led by Dr.